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Overthelastdecade,severalepidemiologicalstudiesbasedonfoodfrequencyquestionnairessuggestthatomega-3polyunsaturated
fattyacidscouldhaveaprotectiveroleinreducingtheonsetandprogressionofretinaldiseases.Theretinahasahighconcentration
of omega-3, particularly DHA, which optimizes ﬂuidity of photoreceptor membranes, retinal integrity, and visual function. Fur-
thermore, many studies demonstrated that DHA has a protective, for example antiapoptotic, role in the retina. From a nutritional
point of view, it is known that western populations, particularly aged individuals, have a higher than optimal omega-6/omega-3
ratioandshouldenrichtheirdietwithmoreﬁshconsumptionorhaveDHAsupplementation.Thispaperunderscoresthepotential
beneﬁcial eﬀect of omega-3 fatty acids on retinal diseases.
1.Introduction
Fattyacidsarecommonlyclassiﬁedassaturated,monounsat-
urated, and polyunsaturated fats. Saturated fats are a chain
of carbon atoms joined by single links (butter, lard, and fat
in meat). Monounsaturated fatty acids (MUFAs) are made
up of a chain of carbon atoms containing one double bond
(olive oil). Polyunsaturated fatty acids (PUFAs) contain at
least two double bonds (Figure 1) and are classiﬁed by the
position of the ﬁrst double bound counting from the methyl
terminal. When the ﬁrst double bond is 6 carbon atoms
from the methyl terminal, PUFAs are called omega-6, ω6,
or n-6, and when the ﬁrst double bound is 3 carbon atoms
from the methyl terminal, PUFAs are called omega-3, ω3,
or n-3 (Figure 1). Two PUFAs, linoleic acid (LA, C18:2n-6),
an omega-6 fatty acid, and α-linolenic acid (ALA, C18:3n-
3), an omega-3 fatty acid, are termed essential because they
are required for optimal health, but cannot be synthesized
by the body. Therefore, these essential fatty acids have to
be supplied by the diet. These omega-6 and omega-3 es-
sential fatty acids can be used by the body either as an en-
ergy source or be transformed with additional bounds, using
elongase and desaturase enzymes into longer-chain PUFAs
(LC PUFAs). However, the endogenous synthesis of LC
PUFAs from the essential precursors LA and ALA is limited,
and the diet needs to supply appropriate amounts of LC
PUFAs. Among omega-6, LA is found mainly in vegetable
products (soybean, sunﬂower, saﬄower, corn oils) and the
major omega-6 LC-PUFA, the arachidonic acid (AA,
C20:4n-6) is present in animal products (meat and egg yolk).
Among omega-3, ALA is found mainly in vegetable products
(rapeseed, canola, and nut oils). Key omega-3 LC PUFAs
include eicosapentaenoic acid (EPA, C20:5n-3) and docosa-
hexanoic acid (DHA, C22:6n-3) (Figure 1), both found pri-
marily in oily cold-water ﬁsh such as tuna, salmon, sardines,
and mackerel. Aside from fresh seaweed, a staple of many
cultures, plant foods rarely contain EPA or DHA.
2. DietaryIntakeand Recommendations
Both omega-6 and omega-3 fatty acids are essential, but the
body requires them in a ratio that is not normally achieved
by the typical diet of today’s industrialized nations. Experts
think that man evolved on a diet which would have had
roughly 1-2 times more omega-6 than omega-3, though
there is a school of thought which argues for a 1:1 ratio [1].
Alaskan Eskimos, whose diet is rich in ﬁsh and marine mam-
mals, have a plasma omega-6/omega-3 PUFA ratio of 3.5:1
[2]. Interestingly, lower rates of cardiovascular disease and
atherosclerosis have been well documented in this native
population [3, 4]. Currently, average intakes in Western
Countries are in a ratio of around 8:1 to 20:1 in favour of2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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the omega-6. The dietary ratio of omega-6/omega-3 con-
sumed in the United States is 10.6:1 [5]. For Western soci-
eties, there are recommendations to decrease the intake of
omega-6 PUFAs and increase the intake of omega-3 PUFAs.
The World Health Organization (WHO) recommends the
consumption of 0.3–0.5g/day [6], while the International
Society for the Study of Fatty Acids and Lipids (ISSFAL)
advocates 500mg/day [7], and the North Atlantic Treaty Or-
ganization (NATO) recommends 800mg/day [8]. The Food
and Drug Administration (FDA) and American heart associ-
ation attribute the cardiovascular beneﬁts of PUFAs to EPA
and DHA and recommend a regular intake of ω3 LC PUFA
intake of 0.9–1.0g/day. A recent publication by the European
Food Safety Authority (EFSA) postulates that the amount of
EPA+DHA required to lower triglyceride levels is 2–4g/day,
and 3g/day to lower blood pressure [9]. Dietary recommen-
dations for ω3 LC PUFA intake for healthy adults have been
set at a minimum of 650mg/d by the International Society
for the Study of Fatty Acids and Lipids [10]. This organi-
sation recommends intake of DHA for adults to be at least
219mg per day and 300mg per day for pregnant and lactat-
ing women. The British Nutrition Foundation recommends
8g EPA plus DHA per week for women (i.e., 1145mg per
day) or 10g EPA plus DHA per week for men (i.e., 1430mg
per day) [11]. DACH association (Association of German,
Austrian and Swiss Societies for Nutrition) recommends an
ideal linoleic acid (omega-6 fatty acid)/alpha-linolenic acid
(omega-3 fatty acid) ratio of 5:1 in the dietary intake [12].
The maximum tolerated dose of EPA plus DHA has been
determined for humans at 300mg/kg of body weight per day,
which for an average-sized man (150lbs) is approximately
22g/day [13].
3. Omega-3 inthe Retina
3.1. Structural Role of Omega-3 in the Retina. Essential fatty
acids are structural components of all tissues and are indis-
pensable for cell membrane synthesis. The structural lipids
of the disk membranes consist primarily of phospholipids
(80–90% of the total lipid) with low levels of cholesterol
(8–10%), a composition that makes them unusually ﬂuid.
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of the fatty acids in most tissues (1–5%), it accounts for
approximately 50–60% of the total fatty acid content within
rod outer segments of photoreceptors (ROSs) [14–16]. It is
demonstrated in piglets that supplementation of dietary
DHA signiﬁcantly increase DHA in brain and retina [17, 18].
To compensate for the continuous oxidative damage, the
photoreceptors have the capacity of continuous renewal.
While new outer segment disks are being generated at the
base of the ROS, old disks at the tip are being phagocytosed
by the cells of the RPE, which also have a very active meta-
bolism,butunlikethephotoreceptorsdonothaveanypoten-
tial to regenerate so that damaged cells cannot be replaced
[19]. In the retina, DHA is mainly but not exclusively located
in photoreceptor cells, where it becomes esteriﬁed into phos-
pholipids. It has been thought to play an important role for
the synthesis of disk membranes, in providing an adequate
environment for conformational rhodopsin changes and in
modifying the activity of retinal enzymes. Approximately, 60
moleculesofphospholipidssurroundeachmoleculeofvisual
pigment. Comparisons between DHA and saturated lipids in
ROS membranes showed that PUFA favor chain extension
while maintaining bilayer ﬂexibility and have a tendency to
adoptahairpin-likestructure,whichincreasedtheinterfacial
area per lipid [20]. Another role is the renewal of outer seg-
ments, which proceeds by the shedding of discs and the
resynthesis of new membranes [21]. A deﬁciency of DHA in
the membranes of photoreceptors disturbs membrane ﬂuid-
ity and function and could alter the process of outer segment
renewal [22]. DHA is also suggested to play a role in early
photoreceptor diﬀerentiation [23].
3.2. Functional Role of DHA in the Retina. The composition
of the membrane lipid bilayer has a direct inﬂuence on the
energy of the conformational states of rhodopsin in visual
excitation [14, 24]. Bush et al. demonstrated that DHA plays
an important role in the regeneration of rhodospin. An 80%
reduction in retinal DHA level in omega-3 deﬁcient rats is
associated with a signiﬁcantly slower rate of rhodopsin rege-
neration after 100% bleach. In fact, interactions between
DHA and rhodopsin occur as early as their cotransport in
the post-Golgi vesicules to ROS [14]. The dependency on
docosahexaenoic acid-containing phospholipid bilayers has
recently been described for the kinetic conversion of meta-
rhodopsin I to metarhodopsin II [25], the formation of ac-
tivated rhodopsin-transducin complex [26], and the acti-
vation of phosphodiesterase [27]. Furthermore, DHA acyl
chains promote the coupling of metarhodopsin II to the reti-
nal G protein [28]. DHA has also signiﬁcant eﬀects on pho-
toreceptormembranesandneurotransmittersinvolvedinthe
signal transduction process, rhodopsin activation, rod and
cone development, neural dendritic connectivity, and func-
tional maturation of the central nervous system [29]. A con-
centration gradient of DHA normally exists in the subretinal
spacebetweentherodoutersegments(higherconcentration)
and the retinal pigment epithelium (lower concentration),
and the release of 11-cis retinal from interphotoreceptor
retinoid-binding protein (IRBP) is facilitated when IRBP is
exposed to suﬃcient DHA in the subretinal space [30, 31].
The role of 22:6n-3 in the retina has not been exactly
deﬁned, although dietary deprivation of this essential fatty
acid or its precursors leads to changes in retinal function in
rats, cats, guinea pigs, and monkeys [32–40]. Benolken et al.
demonstrated that rats fed a fat-free diet for two generations
had abnormally low DHA levels in photoreceptor mem-
branes and low ERG amplitudes [39]. The amplitude of this
light-evoked retinal response increased in proportion to the
amount of omega-3 PUFAs added to the diet. In third-gene-
ration omega-3 PUFA-deﬁcient rats, DHA levels in retina
werereducedby55%[40].Theomega-3-deﬁcientratsexhib-
ited signiﬁcantly reduced retinal sensitivity and increased
b-wave implicit times compared with those fed the n-3-ade-
quate diet.
Carri´ e et al. investigated the eﬀects of DHA deprivation
and supplementation of DHA on behavior, ERG and PUFA
composition in the brain, and retina of old mice [41]. In
deﬁcient mice, supplementation with phospholipids rich in
DHA restored retinal level of DHA and ampliﬁed the b-wave
amplitude on ERG. Dietary provision of DHA during aging
improved the visual abilities both in control and deﬁcient
mice. This study suggests a potential reversibility of retinal
dysfunction linked with omega-3 deﬁciency, even in aged
animals.
The guinea pig provides a model in which dietary
omega-3fattyaciddeﬁciencycouldproducesigniﬁcantredu-
ctionsintheretinalomega-3proﬁleinasinglegeneration.In
guinea pigs, DHA deprivation induces a signiﬁcant decrease
in retinal DHA and decrease in b- and a-waves ERG ampli-
tudes [36]. However, 10-week repletion allowed a complete
functional recovery of both receptoral and postreceptoral
components of the ERG responses [36]. It is notable that
over a certain amount of DHA, essential for normal retinal
function,anincreaseintheretinalDHAlevelpastanoptimal
amount (around 19%) and seems to provide diminishing
returns [35].
Neuringer et al. fed two cohorts of rhesus monkeys diets
that contained either 0.3% ALA (low ALA) or 8% ALA (high
ALA)asthesoleomega-3fattyacid[42,43].Asecondcohort
also included a third dietary group supplemented with LC-
PUFAs (DHA 0.6%, EPA 0.2%, and AA 0.2%). ERGs were
recorded from the monkeys as infants (3-4 months), juve-
niles (1-2 years), and the second cohort as young adults (4–
6 years). In the ﬁrst cohort, low-ALA monkeys had reduced
rod and cone ERG a-wave amplitudes as infants compared
withthehigh-ALAmonkeys.Thesereducedamplitudeswere
not observed in the second cohort whentested as juveniles or
adults. The most marked and consistent alteration in retinal
function in monkeys fed with the low ALA diet was a delay
in the time required for the rod photoreceptors to recover
after a light ﬂash. The reduction in ERG amplitude at short
intervals between ﬂashes suggested a delay in recovery of the
rod photoreceptors, a conclusion recently conﬁrmed in adult
rhesus monkeys by measuring rod recovery [44, 45].
To summarize, studies in mice, rats, guinea pigs, cats,
and rhesus monkeys highlight important species diﬀerences
with respect to the eﬀect of reducing retinal DHA levels on
retinalfunction.Itisunclearwhythesespeciesshouldexhibit
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deﬁcient diet. However, the omega-3 deﬁcient diets used in
each species induced similar changes in retinal fatty acids
[46]. In the ERG studies, rats and guinea pigs fed with
omega-3 deﬁcient diets had retinal DHA levels reduced by
30–65% in comparison with omega-3 suﬃcient control ani-
mals [47]. In the rhesus monkeys, retinal DHA was reduced
by 50% at birth and by 80% at 2 years of age [43]. In each of
the animal studies, the fall in retinal DHA was compensated
for by an increase in retinal 22:5n-6 and, to a lesser extent,
22:4n-6 (AA).
4.ProtectiveRoleofDHAintheRetina
There is an abundance of literature suggesting a protective
role of DHA in the retina, while nutrition is associated with
AMD [48–50]. Some of the mechanisms of protection could
be relevant for the purpose of prevention of AMD.
4.1. Anti-Inﬂammatory Role. It is possible that the anti-in-
ﬂammatoryeﬀectofomega-3alsoplaysapositiverolewithin
the retina. The most signiﬁcant change in the retinal phos-
pholipids fatty acid composition after omega-3 intake is a
large increase in the EPA/AA ratio [51]. In several tissues in-
cluding the eye, the presence of increased levels of omega-3
among phospholipids has been reported to inhibit competi-
tively the formation of cyclooxygenase and lipoxygenase pro-
ducts of AA and to promote the formation of the less potent
omega-3 series eicosanoids, resulting in anti-inﬂammatory
eﬀects [52, 53]. An omega-3 diet also induces a decrease in
theproductionofplateletactivatingfactor(PAF)[54].More-
over, DHA modulates the eﬀects of C-reactive protein, ho-
mocysteine, intercellular adhesion molecules-1 (ICAM-1),
and vascular adhesion molecules (VCAM-1) [55, 56]. Chen
et al. examined the anti-inﬂammatory eﬀects of DHA on
adhesion molecule expression such as ICAM-1 and VCAM-1
induced by cytokines in human retinal vascular endothelial
cells [55]. They suggest that a decrease in DHA leads to the
increase in cytokine-induced proinﬂammatory signaling in
retinal microvasculature.
4.2. Antiangiogenesis Role. Many sight-threatening diseases
have two critical phases, vessel loss followed by hypo-
xia-driven destructive neovascularization. The inﬂuence
of omega-3- and omega-6-polyunsaturated fatty acids on
vascular loss, vascular regrowth after injury, and hypoxia-
inducedpathologicalneovascularizationwasrecentlystudied
by Connor et al. in a mouse model of oxygen-induced re-
tinopathy [56]. They showed that increasing omega-3 PUFA
tissue levels by dietary or genetic means decreased the avas-
cular area of the retina by increasing vessel regrowth after
injury, thereby reducing the hypoxic stimulus for neovascu-
larization. The bioactive omega-3 PUFA-derived mediators
(neuroprotectinD1, resolvinD1, and resolvinE1) protected
against neovascularization. These ﬁndings indicate that in-
creasing the sources of omega-3 PUFA or their bioactive pro-
ducts reduces pathological angiogenesis.
4.3. Antiapoptotic Role. In rat retinal cells cultured in a se-
rum-free medium, the addition of DHA to the cultures pre-
vents the selective apoptotic death of photoreceptors [57].
Comparedwithotherfattyacids,DHAwasnotonlythemost
eﬀective in promoting photoreceptor survival, but also the
only fatty acid to decrease the number of apoptotic nuclei.
In cultures lacking DHA, photoreceptors develop normally
for 4 days and then start an apoptotic pathway leading to
extensive degeneration of these cells by day 11 [58]. In ad-
dition, DHA advances photoreceptor diﬀerentiation, pro-
moting opsin expression and inducing apical diﬀerentia-
tion in these neurons. Furthermore, mitochondrial dam-
age associated with photoreceptor apoptosis is markedly
reduced upon DHA supplementation, suggesting that a pos-
sible mechanism of DHA-mediated photoreceptor protec-
tion might be the preservation of mitochondrial activity.
The authors hypothesized that a critical amount of DHA in
mitochondrial phospholipids might be required for proper
functioning of these organelles, which in turn might be
essential to avoid cell death. It is notable that this protective
eﬀect of DHA can be synergic with the neuroprotective eﬀect
of lutein and zeaxanthin [59].
Rotstein et al. analyzed rat retinal cells in 3-day cultures
treated with the oxidant paraquat, with or without DHA
[57]. They demonstrated that DHA activates intracellular
mechanisms that prevent photoreceptor loss, and modulates
the levels of pro- and antiapoptotic proteins of the Bcl-2
family, protecting photoreceptors from oxidative stress. Sim-
ilarly, it was demonstrated a diet rich in DHA plays a role
in protection against MNU-induced photoreceptor cell apo-
ptosis in the rat retina [60].
The synthesis of a speciﬁc mediator generated from
DHA, the neuroprotectin D1, (NPD1), was recently demon-
strated [61]. NPD1 has interesting properties: it counteracts
tumor necrosis factor alpha oxidative-stress-triggered apop-
totic RPE DNA damage, it upregulates antiapoptotic pro-
teins expression. Moreover, NPD1 protects RPE cells from
oxidative-stress-induced apoptosis, and plays anti-inﬂam-
matory and neuroprotectine roles [39, 62]. This lipid media-
tor therefore may indirectly contribute to photoreceptor cell
survival.
4.4. Protection from Neurotoxicity. T h ep r o t e c t i v ee ﬀect of
DHA against transient retinal ischemia was investigated by
increasingintraocularpressureinrats.WhenDHAisadmin-
isteredbeforeexperimentalischemia,itdiminishedpressure-
induced retinal damage [61]. The recovery of electroretino-
graphic amplitudes after reperfusion is signiﬁcantly greater
in DHA-pretreated eyes than in non-pretreated eyes. Based
on their experiments, Murayama et al. concluded that DHA
prevents sensory retina from ischemic-reperfusion cell dam-
age not only by inhibiting the formation of hydroxyl radicals,
but also by reducing the apoptotic responses [61]. DHA is
in turn involved in the regulation of expression of apoptosis
mediators (Bcl-2 and Bax) preserving mitochondrial mem-
brane potential and inhibiting caspase activation [63, 64].
Miyauchi et al. investigated the ability of DHA to protect
the retina from kainic acid- (KA-) induced retinal damage
[65]. Both morphologic and functional attenuations were
signiﬁcantly less in the DHA-supplemented rats than in
control rats. In this experiment, DHA was able to partially
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DHApromotesphotoreceptorsurvivalanddiﬀerentiationby
activating the same signaling pathways triggered by peptidic
trophic factors.
Yee et al. investigated the role for omega-3 polyunsatu-
rated fatty acid supplements in rats with diabetic retinopathy
[66]. A partial improvement was evident in the oscillatory
potentials at electroretinogram, most likely secondary to the
larger photoreceptor output.
4.5. Enhancement of RPE Acid Lipase Omega-3. The RPE ly-
sosomal acid lipase is an enzyme involved in hydrolysis and
thus the clearance of intralysosomal RPE lipids. Omega-3
ﬁsh oil, delivered to the retinal pigment epithelium (RPE) by
circulating low-density lipoproteins (LDLs), enhances con-
siderably the eﬀects of RPE lysosomal acid lipase [67]. This
was shown in vitro by analysis of RPE cells from monkeys.
Fromtheseexperiments,Elnerhypothesizedthatdietsrichin
ﬁshoil-derivedomega-3fattyacids,byenhancingacidlipase,
may reduce RPE lipofuscin accumulation, RPE oxidative
damage, and then could slow down development of AMD
[67].
4.6. Omega-3 and Peroxidation in the Retina. In the retina,
lipid peroxidation is thought to be a major mechanism con-
tributing to light-induced lesions. Lipid peroxides, found in
theBruch’smembrane,havebeenshowntoinduceneovascu-
larization by inducing expression of a cascade of angiogenic
cytokines [68]. The increase in amount of peroxidized lipids
with age, combined with their vasogenic potential, suggests
that it may play a role in the etiology of neovascular AMD,
particularly choroidal neovascularization. The question of
peroxidizability of ROS with supplementation in DHA has
been raised, and several studies analyzed the levels of hydro-
peroxides in rod outer segments membranes with contra-
dictory results [35, 69]. Owing to its high degree of unsatu-
ration, with 6 double bounds, DHA is vulnerable to peroxi-
dation. This is compounded by exposure to light, high oxy-
gen tension, and high concentrations of retinol [70]. Deple-
tion of retinal DHA by ALA deﬁcient feeding reduces the
susceptibility of the rats ROS to acute light damage, which
appears to be related to the relative levels of DHA [71, 72].
Light-induced stress to the retina in these studies was carried
out by exposing rats to intermittent light with approximately
100 times luminous intensity over the control. In a dietary
supplementation study on young rats fed with high levels
of DHA, it was observed in vitro that ROS membranes
submitted to UV intense irradiation may form phospholipid
hydroperoxides more eﬃciently with higher DHA content
than with low DHA [69]. However, in vivo,a tn o r m a ll i g h t
conditions, there was no increasing tendency in the hydro-
peroxide levels of ROS membranes containing high content
of DHA, which implies that DHA supplementation does not
much aﬀect the peroxidizability of ROS membranes in vivo
[69].
Other studies support the hypothesis of a partial pro-
tective eﬀect of DHA despite increased peroxidation. Reme
et al. investigated the eﬀect of ﬁsh oil on acute light-in-
duced photoreceptor damage in rats in vivo [51]. They ob-
served an enhanced susceptibility to lipid peroxidation in the
isolated retina of ﬁsh oil fed rats. However, ﬁsh oil fed rats
showed less damage at the base of the rod outer segments,
suggesting that omega-3 does not enhance the susceptibility
to acute ROS disk disruptions in the rat retina but exerts
a partial protective eﬀect. Furthermore, Reinboth et al. de-
monstrated that light elicits the in vitro release of DHA from
photoreceptor phospholipids in rats, and proposed that this
release may serve a protective role in the retina by suppress-
ing ARA-derived eicosanoids associated with inﬂammatory
responses [73].
Sunada et al. [74] investigated how dietary DHA aﬀects
the generation of lipid peroxides in rat retina under oxidative
stress in diabetes with/without vitamin E (VE) deﬁciency.
They found, in rats with VE deﬁciency, dietary DHA in-
creased serum and liver lipid peroxide levels but not in the
retina. These results suggest that dietary DHA does not nece-
ssarily promote lipid peroxidation in the retina even under
high oxidative stress.
In parallel to DHA, AA also has a high potential of
peroxidability, 3 times greater than that of ALA [75], medi-
ated by cyclooxygenase and lipooxygenase products of AA
[76]. The F2 isoprostanes (F2-IPs) constitute a novel class of
prostaglandin-F2- (PGF2-) like compounds that are pro-
duced by the non-cyclooxygenase peroxidation of AA [77–
79]. These mediators are reliable markers of oxidative stress
both in vitro and in vivo studies [80, 81]. It was shown in
retina of rats that dietary ﬁsh oil increases the concentration
of DHA and decrease the concentration of AA in ROS [51].
It is thus possible that DHA supplementation could reduce
the levels of F2-IPs in the retina.
Similar to the issue of peroxidation, the percentage of
trans isomers of omega-3 could inﬂuence visual function.
Acar et al. performed ERG in rats feed with ALA in its na-
tural form (cis-isomer) or partially isomerized (cis and trans
isomers) [82]. Dietary trans ALA altered the fatty acid com-
position of retinal phospholipids by signiﬁcantly increasing
the Delta19 trans isomer of DHA. Moreover, dietary trans
isomers of ALA signiﬁcantly decreased the b-wave amplitude
of the ERG by 9 months of feeding, suggesting that long-
term intake of small amounts of trans isomers of ALA could
disturb visual function. The authors hypothesized that it is
at least as important to prevent the consumption of trans
isomers of ALA as to correct the unbalanced omega-6/
omega-3 ratio by increasing the level of the natural isomer
[17].
5. AMD and Omega-3
5.1.EpidemiologyofAMDandOmega-3Consumption. Some
populations such as the Japanese have reported an unusual
low incidence of AMD among their elderly in the past [83].
However, in the last decades, physicians in Japan have re-
ported a signiﬁcant increase in incidence of AMD in their
clinics,particularlyforexudativeAMD[22].Itisalsonotable
that the form of AMD in Japan seemed subtly diﬀerent from
the ones described in Western countries, with less observed
drusen. This population is genetically homogenous, poorly
mixed, without modiﬁcation of the genetic background.
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habits of the population, eating less ﬁsh, and adopting an
occidental diet. The omega-6/omega-3 ratio in Japan is sub-
stantially lower than in the UK and USA. The Japanese ﬁgure
in 1985 (3.9:1) was higher than it was in 1960 (2.9:1) be-
cause of a trend towards lower ﬁsh consumption [84].
Interestingly, a study analyzed the AA and DHA red blood
cells levels in a small Japanese study population aﬀected with
AMD (n = 11) compared with controls (n = 10). No sig-
niﬁcant variations were observed between the two groups in
terms of plasma levels of AA, DHA, palmitic, palmitoleic,
oleic,andlinoleicacids.However,thenumberofpatientswas
small and there was no clear classiﬁcation of AMD [72].
Similarly, in Iceland, the phenotype of ARM and AMD
is diﬀerent from most other North European communities
[85]. This diﬀerence is expressed by the higher preva-
lence of geographic atrophy (more than 80% of advanced
cases) in Iceland compared with other populations. The
predominance of atrophic form of AMD could be genetically
explained by homozygosis (common ancestor). On the other
hand, the relative low prevalence of exudative forms could
be explained by environmental factors such as nutrition. The
Icelandic population is relatively well nourished. According
to the United Nations Food and Agriculture Organization,
no European nation eats more ﬁsh per capita than Icelanders
although their consumption of green vegetables and fruits
is relatively low by European standards [86]. Unfortunately,
the possibility that Icelandic emigrants might develop more
wet AMD has not yet been investigated, which would assess
the roles of nutrition and other environmental factors versus
genetic protection.
5.2.FishConsumptionPrevalenceandIncidenceofAMD. The
hypothesis of a relationship between omega-3 and AMD has
been evaluated in many studies of dietary intake [87, 88].
Sanders et al. performed a matched-control study of PUFAs
content of plasma and RBCM on 65 AMD patients and 65
controls [89]. They did not observe any diﬀerence in con-
centrations of DHA between AMD patients and controls in
the serum or in the RBCM. The sample size was small and
most of the AMD patients included in this study were af-
fected with drusen and/or pigment changes, but only two
were aﬀected with neovascular AMD.
Studies which investigated the relationship between con-
sumption of omega-3, based on frequency food question-
naire (FFQ), and the occurrence of AMD. It is notable that
these diﬀerent studies, analyzing diﬀerent populations, all
suggest a protective eﬀect of omega-3 ﬁsh oil.
The ﬁrst report of a statistical analysis showing the eﬀect
of the relationship between dietary omega-3 fatty acids and
AMD was presented at the ARVO meeting in 1994 [90]. The
Ancillary Dietary Study of the Eye Disease Case-Control
Study included 349 patients with exudative AMD and 504
unaﬀectedcontrols,anddemonstratedastrongpositiveasso-
ciation between exudative AMD and consumption of all fats
andaninverseassociationwithﬁshoil[86].Astrongassocia-
tionwasobservedbetweenhigherlinoleicacidintakeandthe
disease, with an odd ratio (OR) in multivariate analyses for
the 5th versus the 1st quintile of 2.0 (P = 0.02). Conversely,
intake of omega-3 fatty acids showed an inverse relationship
with AMD in demographically adjusted analyses (OR: 0.59,
P = 0.01), but the signiﬁcance of the association decreased
after multivariate analyses, with an odd ratio of 0.75. In in-
dividuals consuming low omega-6 (linoleic acid) and high
omega-3, the relative risk of exudative AMD was 0.60.
In 1995, Mares-Perlman et al. [87] reported the results of
the Beaver Dam Eye Study, that included 1968 participants,
including 314 early ARM individuals but only 30 late AMD
patients (21 wet AMD and 9 geographic atrophy). Intake of
seafood, considered as a marker of intake of omega-3 fatty
acids, was unrelated to early or late macular degeneration.
The calculations were made in g/4200kJ, comparing quintile
5 to quintile 1. The odds ratio for early ARM was 0.9
(P = 0.3) and odds ratio for late ARM was 0.8 (P = 0.4).
However, the low number of patients aﬀected with late AMD
limited the power of this study.
IntheBlueMountainsEyeStudypopulation,aclearasso-
ciation was observed between higher frequency of intake of
ﬁsh (>1 per week) with decreased risk of late age ARM [91],
compared with lower frequency of consumption (<1p e r
month) with an odds ratio approximately at 0.5 [92]. More
precisely, when they compared the higher frequency (≥5p e r
week) to the lower frequency of intake of ﬁsh (<1p e r
month), the odds ratio adjusted for age, sex, smoking status,
and familial history of late ARM was at 0.46 for late ARM.
To investigate the longitudinal associations between dietary
fat and incident age-related ARM, 3654 persons who partici-
patedintheBlueMountainsEyeStudywerereexaminedafter
5y ears[93].Participantswiththehighestversuslowestquin-
tiles of omega-3 polyunsaturated fat intake had lower risk of
incident early ARM (OR: 0.41), whereas ﬁsh consumption at
least3timesperweekcouldreducetheincidenceoflateARM
(OR: 0.25).
The third National Health and Nutrition Examination
Survey(NHANESIII)describedsimilarassociationsbetween
fats and AMD in a cross-sectional study [94]. The AMD sta-
tus was based on fundus photography of one eye in 7883
participants, and the intake of fats was based on a FFQ.
Among them, 644 were classiﬁed as early ARM and a small
number of individuals with advanced AMD was observed
(n = 53).Afteradjustmentforage,race,eyecolor,andseden-
tary lifestyle, the odd ratio for early ARM was 1.4 (P = 0.10)
comparing the 5th versus the 1st quintile. They did not
observe a similar relationship for advanced AMD but the
small number of these patients limited the power of this
study. Nevertheless, they found that consumption of ﬁsh
more than once a week compared with once a month or less
was associated with odd ratio of 1.0 for early ARM and 0.4
for late ARM (P = 0.10) after adjusting for age and race.
In the Nurses’ Health study [95], total fat intake was also
associated with an increased risk of AMD. Linolenic acid was
positively associated with risk of AMD; the highest quintile
of intake was associated with a 49% increased risk compared
with the lowest quintile. Adjustment for total fat and trans-
unsaturated fat did not attenuate the RR for AMD. In con-
trast, DHA intake had an inverse relation with AMD; the
pooled multivariate relative risk for the highest quintile of
DHA intake compared with the lowest was 0.70. Participants
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thosewhoconsumedit<4timespermonth(RR:0.65).More
speciﬁcally, the pooled relative risk of participants who ate
canned tuna more than once per week compared with those
who consumed it less than once per month was 0.61.
T h eU ST w i nS t u d yo fA g e - R e l a t e dM a c u l a rD e g e n e r a -
tion [50] also investigated risk for AMD, according to dietary
fat intake in 221 twins with AMD (intermediate or late
stages) and 459 twins with no maculopathy or early signs.
The authors found that dietary omega-3 fatty intake was in-
versely associated with AMD, comparing the highest versus.
lowest quartile (OR: 0.55). Reduction in risk of AMD with
higher intake of omega-3 fatty acids was seen primarily
among subjects with low levels of omega-6 fatty acids.
The EUREYE study [96], analysing the diet of European
elderly, found that eating oily ﬁsh at least once a week com-
pared with less than once a week is associated with a halving
of the odds of neovascular AMD (OR: 0.47; P = 0.003).
Compared to the lowest quartile there was a signiﬁcant trend
for decreased odds with increasing quartiles of either DHA
or EPA (odds ratios in the highest quartiles were OR: 0.32,
P = 0.04 for DHA, and OR: 0.29, P = 0.02 for EPA).
The POLANUT study also recently assessed the associa-
tions of dietary fat with the risk of ARM, in 832 subjects aged
70 years or more of the POLA (Pathologies Oculaires Li´ ees
` al ’ A g e )c o h o r ts t u d y[ 97]. Subjects in the highest quintile
of energy-adjusted total, saturated, and MUFA intake were
associatedwith increased risk forARM (OR:4.74,P = 0.007;
OR:2.70,P = 0.04;OR:3.50,P = 0.03,resp.),bycomparison
with subjects in the lowest quintile. Total PUFA was not
signiﬁcantly associated with ARM (OR: 1.02, 95% CI: 0.29–
3.53, P = 0.94), but fatty ﬁsh intake (more than once a
month versus less than once a month) was associated with
a 60% signiﬁcant reduction in risk for ARM (OR: 0.42;
P = 0.01). This study is consistent with increased risk of
ARM in subjects with high dietary intake of fat (in particular
high MUFA intake) and conversely suggests a potential
protective eﬀect of long-chain 3 PUFA.
Hodge et al. [98] reviewed the literature without restric-
tion and concluded that the eﬃcacy of dietary and/or sup-
plementalomega-3fattyacidsinpreventingAMDwasneith-
erclearlysupportednorrefutedbytheworldliterature.How-
ever, despite the diﬀerences in methodology and popula-
tions, all of these studies suggested a protective role of DHA
for AMD, particularly for exudative AMD. Moreover, the
inverse relationship between omega-3 ﬁsh oils highly con-
trasts with the positive association between other types of
fat and AMD [99]. Further studies with prospective cohort
designs and randomized clinical trials are needed.
The AREDS group also investigated the role of omega-3
PUFAs in the occurrence of exudative AMD [100]. They ob-
served a signiﬁcant lower relative risk of neovascular AMD
associatedwithhigherconsumptionofomega-3(the5thver-
susthe1stquintile),withanoddratioat0.61(P<0.01).This
inverse relationship was even more signiﬁcant when ana-
lyzing speciﬁcally the higher versus. lower consumption of
DHA, with an odds ratio at 0.54 (P<0.004). Higher ﬁsh
consumption, both total and broiled/baked, was also in-
versely associated with NV AMD (OR: 0.61 and OR: 0.65,
resp.).Conversely, dietaryarachidonic acidwasdirectlyasso-
ciated with NV AMD prevalence (OR: 1.54).
5.3. Fish Consumption and Progression of AMD. A prospec-
tive cohort study based on an FFQ evaluated the potential
role of fat intake on the progression from early or interme-
diate forms of AMD to advanced forms of AMD. This study
suggested a protective eﬀect of ﬁsh intake among individuals
with lower linoleic acid intake [49]. There was a positive as-
sociation between higher saturated, monounsaturated, poly-
unsaturated fat, and transunsaturated fat intake and pro-
gression of AMD, with multivariate RR’s, respectively, of
2.09 (P = 0.08), 2.21 (P = 0.04), 2.28 (P = 0.04), 2.39
(P = 0.008). The analysis of relatives risks for progression
to advanced AMD by frequency of ﬁsh intake did not reveal
a signiﬁcant diﬀerence between individuals eating less than
oneservingofﬁshperweekandindividualseatingmorethan
once a week (RR: 0.88; P = 0.42). However, when subjects
were stratiﬁed by linoleic acid, the major source of omega-6
fattyacids,ﬁshintakedecreasedtheriskofAMDprogression
when LA was below the median, with a multivariate RR of
0.36 (P = 0.045). Consumption of nuts also seemed to have
ap r o t e c t i v ee ﬀect on the progression of AMD, with a mul-
tivariate RR of 0.60 (P = 0.05) when comparing individuals
eating nuts more than once a week versus. none. This could
be explained by the presence of linolenic acid (ALA), pre-
cursor of DHA, in nuts. The main advantage of this study is
the large size of patients and its prospective design.
In contrast to all of the other studies to date, an Aus-
tralian prospective study found a positive association bet-
ween intake of omega-3 and progression of AMD (OR: 2.56,
P = 0.03) [101]. This study included 254 individuals, fol-
lowed during 7 years. In their discussion, the authors suggest
the possibility that participants of this study adopted a more
healthy diet, having been aware of their AMD status at the
beginning of the study.
5.4. Interventional Studies. To the best of our knowledge,
very few clinical trials investigated the role of oral supple-
mentation with omega-3 for the prevention of AMD. A
French study called NAT-1 (Nutritional AMD Treatment,
phase 1) evaluated the feasibility of a prospective interven-
tionalstudyfororalsupplementationwithﬁshoilinahomo-
genous AMD population [102]. A homogeneous group of 38
patients aﬀected with drusenoid pigment epithelial detach-
ment in one eye (PED) without choroidal new vessels (CNV)
wasstudied.Thepopulationwasdividedintotwosubgroups,
with(n = 22)orwithout(n = 16)omega-3supplementation
(EPA: 720mg/day and DHA: 480mg/day), over a 6-month
period. A signiﬁcant blood enrichment in EPA in serum (S)
and in red blood cell membranes (RBCMs) (EPA-S: 2.20%
versus 0.79%, P< 0.0001 and EPA-RBCM: 2.24% versus
0.85%, P<0.0001) and in DHA (DHA-S: 2.47% versus
1.56%, P<0.0001 and DHA-RBCM: 6.47% versus 4.67%,
P<0.0001) was observed in the treated group at the 6th-
monthvisit.Theabsorptionofomega-3PUFAsdidnotseem
to be altered in this aged population. During this short per-
iod of time, no progression was observed in the size of the
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CNV was noted in any of the two groups. Neither side eﬀects
nor dropouts were observed. NAT-1 supported for the feasi-
bility of a long-term double-masked prospective study in an
AMD population in order to evaluate the potential beneﬁt
from oral supplementation with DHA.
An Italian study analyzed the beneﬁt of supplementation
with Mitotrop, a product containing acetyl-L-carnitine,
omega-3 and coenzyme Q10 [103, 104]. A total of 106 pa-
tients with early AMD were included within a period of 12
months of treatment. Visual function was evaluated by best
corrected visual acuity and by analysis of 10 degree visual
ﬁeld mean defect. In the treated group, the visual function
showed slight improvement and the divergence between
treated and control groups became more marked with time,
but not statistically signiﬁcant. The authors supported that
the association of these compounds may improve retinal
function in early AMD.
A study conducted at 5 independent study sites, the
TOZALstudy,investigatedthechangefrombaselineinvisual
functionat6monthsin37subjectswithatrophicAMDtreat-
ed with a targeted nutritional supplement (taurine, omega-3
fattyacids,zinc,antioxidant,lutein)[105].Therewasastatis-
ticallysigniﬁcantimprovementinvisualacuityfrombaseline
compared to a placebo-cohort constructed from the litera-
ture that was matched for inclusion and exclusion criteria
(P = 0.045). The results of the TOZAL study agree with the
LAST [95] and CARMIS studies and are predictive for posi-
tive visual acuity outcomes in clinical trials of omega-3 sup-
plementation.
The OPAL study [106]h a sb e e nr e c e n t l yl a u n c h e dt o
asses if an increased dietary intake of n-3 PUFAs will have
ap o s i t i v ee ﬀect on cognitive performance in older people in
the UK. To test this hypothesis, a double-blind randomised
placebo-controlled trial will be carried out among adults
aged 70–79 years in which the intervention arm will receive
daily capsules containing n-3 PUFAs (0.5g/day DHA and
0.2g/day EPA), while the placebo arm will receive daily cap-
sules containing olive oil. The main outcome variable asses-
sed at 24 months will be cognitive performance and a second
major outcome variable will be retinal function.
The NAT-2 is a monocentric prospective, interventional,
randomized, and double-masked trial conducted in France.
Criteria for inclusion are presence of CNVs in one eye only,
and presence of drusen in the study eye (n = 298 AMD
patients). A complete ophthalmologic examination is per-
formed including best-corrected visual acuity, multifocal
ERG, ﬂuorescein angiography (FA), OCT, as well as a com-
plete lipid proﬁle including cholesterol, triglycerides, LC-
PUFAs in the serum and red blood cell membranes (RBCM),
and ApoE genotype. All individuals, in the treated and un-
treatedgroupsarefollowedfor3years.Theprimaryoutcome
istheoccurrenceofchoroidalneovascularizationinthestudy
eye. The secondary parameters are the evolution of the visual
function (visual acuity and multifocal ERG), the occurrence
of atrophy, and the evolution of drusen (quantity and area).
Preliminary results of NAT–2 revealed that HDL level mean
(95% CI) was particularly elevated in the NAT-2 popu-
lation (298 patients from the NAT-2 study at baseline)
(1.74mmol/L) versus healthy age and sex-matched French
population (2030 individuals without any drusen or macular
lesion) (1.37mmol/L) (P<0.0001) [107]. This ﬁnding is in
agreement with a recent study [74] reporting that increasing
HDL cholesterol is inversely related to incident late AMD
(RR per standard deviation [SD] increase, 0.74). Mean
MUFAs level was also elevated in the NAT-2 population
(24.9%) versus non-AMD population (20.4%) (P<0.0001).
Mean omega-6, omega-3, and DHA levels were lower in the
NAT-2 population (resp., 32.4%, 2.34%, and 1.28%) ver-
sus non-AMD population (resp., 37.2%, 3.06%, and 1.89%)
(P<0.0001).Therefore,highHDLlevelsandlowPUFAslev-
els were observed particularly low DHA levels, in exudative
AMD patients. These ﬁndings support the potential beneﬁt
of DHA supplementation in AMD patients.
The AREDS-2 study is a multicenter-randomized trial
designed to assess the eﬀects of oral supplementation of
high doses of macular xanthophylls (lutein and zeaxanthin)
and/or omega-3 LCPUFAs (DHA and EPA) on progression
to advanced AMD [108]. This objective will be accomplished
by collecting and assessing the data on approximately 4000
AREDS 2 participants aged from 50 to 85 years, who at the
time of enrolment have either (1) bilateral large drusen or
(2) large drusen in one eye and advanced AMD (neovascular
AMD or central geographic atrophy) in the fellow eye. All
participants will be oﬀered additional treatment with the
study formulation used in AREDS. For those who elect to
take this additional supplement, which is now considered the
standard of care, further randomization may occur to eva-
luate the possibility of deleting beta-carotene [109]a n dd e -
creasing the original levels of zinc in the formulation for
the treatment of AMD, if consent is obtained. Study par-
ticipants are therefore assigned randomly to take one of the
followingstudysupplementsonadailybasis:(1)placebo,(2)
Lutein/zeaxanthin (10mg/2mg), (3) DHA/EPA (1g), or (4)
Lutein/zeaxanthin and DHA/EPA (10mg/2mg and 1mg),
with a secondary randomization involving modiﬁed doses of
AREDS 1 supplements.
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